SARC SARC Participant Login
 
 
Collaborating for a Cure.
 



 

 

 

 

Article - Detail

7/11/2007
Survival for Soft Tissue Sarcoma Patients Improved at High-volume Centers

According to an article recently published in Annals of Surgery, survival and physical function for patients with soft tissue sarcoma (STS) are significantly improved for those treated at a medical center that treats high volumes of patients with this disease when compared with medical centers that treat lower volumes.

Soft tissue sarcoma refers to a group of cancers that may originate from several types of soft tissues in the body such as fat, muscle, and ligaments. Depending on the type of STS present, STS may be found at several different anatomical locations in the body. Patients with STS of the limbs must often undergo surgical removal of at least the partial limb; however physicians try to limit the degree of amputation through pre-operative therapy.

Results from several recent clinical studies have indicated that patients with various types of cancers may experience improved survival when treated at hospitals that treat a high volume of patients with their specific disease or when they are treated by physicians who specialize in their disease.

Researchers from Florida recently conducted a clinical study to further evaluate the link between hospital and physician volume and outcomes for STS. This study included 4,205 patients registered in the Florida Cancer Data System (FCDS) who were treated between 1981 and 2001. High-volume medical centers were defined as "facilities above the 67th percentile for volume" in comparison with other centers with regards to treatment for patients with STS.

  • A higher proportion of aggressive-type cancers and large cancers were surgically removed at high-volume centers.
  • Among patients with aggressive-type cancers, median survival was 30 months for patients treated at high-volume centers compared with 24 months for those treated at lower-volume centers.
  • Among patients with larger cancers (over 10 cm), median survival was 28 months for those treated at high-volume centers compared with 19 months for those treated at lower-volume centers.
  • Patients with STS on their trunk or sides of lower back had an eight-month median improved survival when treated at a high-volume center.
  • Amputation of a limb occurred at a significantly lower rate at a high-volume center than a lower-volume center (9.4% versus 13.8%, respectively).

The researchers concluded that patients with STS have significantly improved survival and functional outcomes when treated at a high-volume center, particularly patients with large or aggressive cancers or those with cancers located on the trunk of the body. Patients with STS may wish to consider treatment at a high-volume medical center.

Reference: Gutierrez J, Perez E, Moffat F, et al. Should soft tissue sarcomas be treated at high-volume centers?: An Analysis of 4205 Patients. Annals of Surgery. 2007;245:952-958.

Thursday, June 29, 2000
Managing Chemotherapy Side Effects Can Lead to a Summer of Strength
view

Friday, November 10, 2000
Synovial Sarcoma: A Clinicopathologic, Staging, and Prognostic Assessment
view

Friday, January 03, 2003
Insulin-like growth factor-I receptor activation blocks doxorubicin cytotoxicity in sarcoma cells
view

Thursday, April 10, 2003
Synovial Sarcoma of Childhood and Adolescence: A Multicenter, Multivariate Analysis of Outcome
view

Sunday, May 01, 2005
Antitumor Activity of the Insulin-Like Growth Factor-I Receptor Kinase Inhibitor NVP-AEW541 in Musculoskeletal Tumors
view

Thursday, May 05, 2005
A Look At Bone Sarcomas Past and Present
view

Wednesday, August 10, 2005
Rhabdomyosarcoma: New Windows of Opportunity
view

Sunday, September 04, 2005
The Growing Role of the mTOR Pathway
view

Monday, September 12, 2005
Cancer Treatment Related Changes in Cognitive Function (a.k.a. "Chemo Brain")
view

Tuesday, July 04, 2006
New Emerging Drugs in Soft Tissue Sarcoma
view

Thursday, August 24, 2006
The Role of the IGF System in Cancer Growth and Metastasis: Overview and Recent Insights
view

Tuesday, September 05, 2006
Soft Tissue Sarcoma

Thursday, January 25, 2007
Cancer Pathway Exposed
view

Sunday, May 20, 2007
Multiple Drug Resistance in Osteogenic Sarcoma: INT0133 From the Children's Oncology Group
view

Monday, May 28, 2007
Gemcitabine and Docetaxel in Metastatic Sarcoma: Past, Present, and Future
view

Wednesday, July 11, 2007
Survival for Soft Tissue Sarcoma Patients Improved at High-volume Centers
view

Tuesday, September 04, 2007
Anatomy of a Visit - Behind the Waiting Room Walls in the UM Cancer Center

Wednesday, September 12, 2007
Kaposi Sarcoma
view

Thursday, September 13, 2007
Ewing Sarcoma
view

Thursday, November 08, 2007
Gastrointestinal Stromal Tumours and Imatinib
view

Friday, November 09, 2007
13th Annual CTOS SARC Agenda Book

Friday, November 16, 2007
Pediatric sarcomas occurring in adults
view

Wednesday, January 02, 2008
SARC: An Effort to Perform Clinical Trials More Efficiently and Effectively for People with Sarcoma
view

Saturday, January 05, 2008
Therapeutic Potential of Directed Tyrosine Kinase Inhibitor Therapy in Sarcomas
view

Monday, January 28, 2008
Chordoma: The Nonsarcoma Primary Bone Tumor
view

 
Sitemap | Terms of Use | Contact Us SARC | 24 Frank Lloyd Wright Drive, Lobby A, Suite 3100 | Ann Arbor, MI 48106 | phone 734.930.7600 | fax 734.930.7557